APA (7th ed.) Citation

S, S. G., S, F., B, E., F, E., MD, S., SK, S., . . . CA, S. (2025). Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 months. Human vaccines & immunotherapeutics, 21(1), 2557676. https://doi.org/10.1080/21645515.2025.2557676

Chicago Style (17th ed.) Citation

S, Schnyder Ghamloush, et al. "Safety and Immunogenicity of an MRNA-based RSV Vaccine in Seropositive Children Aged 12-59 months." Human Vaccines & Immunotherapeutics 21, no. 1 (2025): 2557676. https://doi.org/10.1080/21645515.2025.2557676.

MLA (9th ed.) Citation

S, Schnyder Ghamloush, et al. "Safety and Immunogenicity of an MRNA-based RSV Vaccine in Seropositive Children Aged 12-59 months." Human Vaccines & Immunotherapeutics, vol. 21, no. 1, 2025, p. 2557676, https://doi.org/10.1080/21645515.2025.2557676.